Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Sodium-glucose cotransporter 2 inhibitor use and risk of liver-related events in patients with type 2 diabetes: A meta-analysis of observational cohort studies.
Diabetes Care 48, 1042-1052 (2025)
BACKGROUND: There is uncertainty regarding effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the risk of major adverse liver-related outcomes (MALOs). PURPOSE: We performed a meta-analysis of observational cohort studies to quantify the magnitude of the association between SGLT2 inhibitor use and risk of developing MALOs for people with type 2 diabetes mellitus (T2DM). DATA SOURCES: We systematically reviewed three large electronic databases from inception to January 2025. STUDY SELECTION: We included active-comparator, new-user cohort studies with comparison of SGLT2 inhibitors versus other glucose-lowering medications in patients with T2DM. DATA EXTRACTION: The primary outcome was incidence rate of MALOs defined as a composite of hepatic decompensation events, hepatocellular carcinoma, liver transplantation, or liver-related deaths. Secondary outcomes included each of the above as individual events. Meta-analysis was performed with random-effects models. DATA SYNTHESIS: We identified eight cohort studies with aggregate data on 626,104 patients with T2DM (397,806 SGLT2 inhibitor new users and 228,298 new users of other glucose-lowering agents). During a median of 2.7 years, SGLT2 inhibitor use was associated with significantly lower risk of MALOs (random-effects hazard ratio 0.83, 95% CI 0.72-0.95; I2 = 83.1%) and liver-related deaths (0.64, 0.50-0.82; I2 = 0%). The significant risk reduction in MALOs was observed in comparisons of SGLT2 inhibitors with dipeptidyl peptidase 4 inhibitors, metformin, or pioglitazone but not glucagon-like peptide 1 receptor agonists. Sensitivity analyses did not modify these results. A funnel plot did not show significant publication bias. LIMITATIONS: Observational design of the cohort studies and high level of heterogeneity are the main limitations. CONCLUSIONS: SGLT2 inhibitor use was associated with lower risk of MALOs for patients with T2DM.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Sglt2 Inhibitors
ISSN (print) / ISBN
0149-5992
e-ISSN
1935-5548
Journal
Diabetes Care
Quellenangaben
Volume: 48,
Issue: 6,
Pages: 1042-1052
Publisher
American Diabetes Association
Publishing Place
Alexandria, Va.
Non-patent literature
Publications
Reviewing status
Peer reviewed
Grants
University School of Medicine of Verona, Verona, Italy
Italian PNRR-MAD-2022-12375656 project, Research Projects of National Relevance (Progetti di Rilevante Interesse Nazionale
Italy Ministry of Education, Universities and Research (MIUR) under the National Recovery and Resilience Plan
National Institute for Health Research (NIHR) Southampton Biomedical Research Centre
Italian PNRR-MAD-2022-12375656 project, Research Projects of National Relevance (Progetti di Rilevante Interesse Nazionale
Italy Ministry of Education, Universities and Research (MIUR) under the National Recovery and Resilience Plan
National Institute for Health Research (NIHR) Southampton Biomedical Research Centre